Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02990481 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Toray Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02990481: Completed Phase 1 study, sponsored by Toray Industries.
NCT02990481 is a Phase 1 study that has completed, run by Toray Industries. The registered enrollment target is 38 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02990481, a Phase 1 study, has completed, sponsored by Toray Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
Interventions
- BIOLOGICAL TRK-950
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2019-09-16 |
| Phase | Phase 1 |
What the finished NCT02990481 record still lists
NCT02990481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 1 intervention - of which TRK-950 is the first listed.
NCT02990481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02990481 about?
NCT02990481 is a clinical study titled "A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors". 1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
What is the current status of trial NCT02990481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-03-06. Estimated completion is 2019-09-16.
What interventions are being tested in trial NCT02990481?
The interventions under investigation include: TRK-950 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02990481?
This trial is sponsored by Toray Industries, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02990481's enrollment target sits among peer trials
38 1197th of 2000 higher than 797 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI